JAMES LLOYD MOHLER, MD
Urology at Elm And Carlton St, Buffalo, NY
License number
New York 227897
Category
Radiology
Type
Urology
Address
Address
Elm And Carlton St, Buffalo, NY 14263
Phone
(716) 845-2300
(716) 845-3300 (Fax)
(716) 845-3300 (Fax)
Personal information
See more information about JAMES LLOYD MOHLER at radaris.comName
Address
Phone
318 W 77Th St APT 5B, New York, NY 10024
23 Lincoln Woods Ln, Buffalo, NY 14222
318 77Th St, New York, NY 10024
318 W 77Th St #5B, New York, NY 10024
318 77Th St, New York, NY 10024
Professional information
Dr. James L Mohler, Buffalo NY - MD (Doctor of Medicine)
Specialties:
Urology
Address:
Roswell Park Cancer Institute
Elm And Carlton St, Buffalo 14263
(716) 845-2300 (Phone)
Amhurst
100 College Pkwy SUITE 290, Williamsville 14221
(716) 845-2300 (Phone)
Elm And Carlton St, Buffalo 14263
(716) 845-2300 (Phone)
Amhurst
100 College Pkwy SUITE 290, Williamsville 14221
(716) 845-2300 (Phone)
Certifications:
Urology, 1997
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Roswell Park Cancer Institute
Elm And Carlton St, Buffalo 14263
Amhurst
100 College Pkwy SUITE 290, Williamsville 14221
Miami Valley Hospital
1 Wyoming St, Dayton 45409
Cleveland Clinic
9500 Euclid Ave, Cleveland 44195
Roswell Park Cancer Institute
Elm And Carlton St, Buffalo 14263
Elm And Carlton St, Buffalo 14263
Amhurst
100 College Pkwy SUITE 290, Williamsville 14221
Miami Valley Hospital
1 Wyoming St, Dayton 45409
Cleveland Clinic
9500 Euclid Ave, Cleveland 44195
Roswell Park Cancer Institute
Elm And Carlton St, Buffalo 14263
Education:
Medical School
Medical College Of Georgia School Of Medicine
Graduated: 1980
Duke University Med Center
Johns Hopkins Hospital
University Of Ky Hospital
Medical College Of Georgia School Of Medicine
Graduated: 1980
Duke University Med Center
Johns Hopkins Hospital
University Of Ky Hospital
James Lloyd Mohler, Buffalo NY
Specialties:
Urologist
Address:
Elm And Carlton Sts, Buffalo, NY 14263
Limited To Official Government Duties On, Buffalo, NY 14263
Limited To Official Government Duties On, Buffalo, NY 14263
Board certifications:
American Board of Urology Certification in Urology
Method For Determination Of Dht Levels In Tissue Samples
US Patent:
2008017, Jul 24, 2008
Filed:
Oct 8, 2007
Appl. No.:
11/973127
Inventors:
James L. Mohler - Buffalo NY, US
Mark Titus - East Amherst NY, US
Kenneth Tomer - Cary NC, US
Mark Titus - East Amherst NY, US
Kenneth Tomer - Cary NC, US
International Classification:
C12Q 1/02, G01N 33/92
US Classification:
435 29, 436 71
Abstract:
Provided is a method for determining the presence or amount of 5-α-dihydro-3-keto steroids (ADKSs) comprising the steps of preparing a sample for chromatographic separation, subjecting the sample to chromatographic separation, subjecting the chromatographically separated sample to atmospheric pressure photoionization (APPI), and detecting the amount of alkylated parent ions using mass spectrometry or methylated daughter ions by mass spectrometry after collisionally induced dissociation of the alkylated parent ions. Tandem mass spectrometry of ADKSs with a 6-member A ring and a 3-keto group using APPI and methanol as the alkoxy donor will produce methylated daughter ions with a mass/charge ratio of 85.0. Quantitation of this alkylated daughter ion provides a method to detect very low levels of ADKSs such as DHT. This method can also be used for the simultaneous detection of ADKSs and non-ADKSs.
Novel Steroid 5Alpha-Reductase
US Patent:
2006027, Dec 7, 2006
Filed:
May 10, 2006
Appl. No.:
11/432424
Inventors:
James Mohler - Buffalo NY, US
Mark Titus - Chapel Hill NC, US
Olga Kozyreva - Chapel Hill NC, US
O. Ford - Wake Forest NC, US
Elsbieta Kawinski - Orchard Park NY, US
Yun Li - Orchard Park NY, US
Mark Titus - Chapel Hill NC, US
Olga Kozyreva - Chapel Hill NC, US
O. Ford - Wake Forest NC, US
Elsbieta Kawinski - Orchard Park NY, US
Yun Li - Orchard Park NY, US
International Classification:
C12Q 1/68, G01N 33/574, C12N 9/02, C12N 15/861
US Classification:
435006000, 435007230, 435189000, 435456000, 435183000
Abstract:
The invention provides an isolated, novel steroid 5α-reductase enzyme termed SRD5AIII. The protein has an estimated molecular weight of 37 kDa and is capable of converting testosterone to dihydrotestosterone at a pH of about 7.0. Also provided is a method for identifying inhibitors of SRD5AIII by contacting SRD5AIII with a test compound and measuring the activity of the enzyme. A reduced activity relative to a control indicates that the test compound is an inhibitor of SRD5AIII. A method is also provided for detecting androgen stimulated prostate cancer or recurrent prostate cancer in an individual. The method comprises obtaining a prostate biopsy from an individual and determining the level of expression of SRD5AIII gene or protein relative to a normal control. An increased expression of SRD5AIII relative to the control is indicative of androgen stimulated prostate cancer or recurrent prostate cancer.
Steroid 5Α-Reductase
US Patent:
8241845, Aug 14, 2012
Filed:
Mar 16, 2009
Appl. No.:
12/404590
Inventors:
James L. Mohler - Buffalo NY, US
Mark Titus - Chapel Hill NC, US
Olga Kozyreva - Chapel Hill NC, US
Elsbieta Kawinski - Orchard Park NY, US
Yun Li - Orchard Park NY, US
Mark Titus - Chapel Hill NC, US
Olga Kozyreva - Chapel Hill NC, US
Elsbieta Kawinski - Orchard Park NY, US
Yun Li - Orchard Park NY, US
Assignee:
Health Research Inc. - Buffalo NY
International Classification:
C12Q 1/68, C12Q 1/26, C12N 15/53, C12N 9/02
US Classification:
435 6, 435 25, 435189
Abstract:
The invention provides an isolated, novel steroid 5α-reductase enzyme termed SRD5AIII. The protein has an estimated molecular weight of 37 kDa and is capable of converting testosterone to dihydrotestosterone at a pH of about 7. Also provided is a method for identifying inhibitors of SRD5AIII by contacting SRD5AIII with a test compound and measuring the activity of the enzyme. A reduced activity relative to a control indicates that the test compound is an inhibitor of SRD5AIII. A method is also provided for detecting androgen stimulated prostate cancer or recurrent prostate cancer in an individual. The method comprises obtaining a prostate biopsy from an individual and determining the level of expression of SRD5AIII gene or protein relative to a normal control. An increased expression of SRD5AIII relative to the control is indicative of androgen stimulated prostate cancer or recurrent prostate cancer.